Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD: An Open-Label Study
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study aims to examine the efficacy of atomoxetine in treating symptoms of attention deficit hyperactivity disorder (ADHD) in children with severe autistic disorder. METHOD: Children with severe autistic disorder who had symptoms of ADHD were given atomoxetine for 10 weeks. The efficacy of atomoxetine was evaluated by using the Aberrant Behavior Checklist (ABC) to rate ADHD symptoms at baseline, week 6, and week 10. The Clinical Global Impression-Improvement (CGI-I) scale was used as secondary outcome to assess the overall improvement of the children's development at week 10. RESULTS: A total of 12 children participated in this study. Although CGI-I scores showed improvement at week 10, the ABC hyperactivity subscale did not show a significant improvement of the ADHD symptoms at baseline (M = 33.89) compared to those at week 10 (M = 31.78, p = .62). CONCLUSION: Atomoxetine did not benefit children with severe autistic disorder who have ADHD symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a separate investigation, atomoxetine treatment yielded no observed symptom reduction in a sample of children with high ASD symptom severity [46].”
From Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder (2012) · cites this paper as [46]
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Diagnostic and Statistical Manual of Mental Disorder
Ellsworth, P. D. (1980) · The American Journal of Occupational Therapy · doi:10.5014/ajot.34.12.819a · Cited by 1,700
(1985) · PubMed · Cited by 1,427
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599 · cited 2×
“…could be a potential alternative treatment for attention deficit and hyperactive symptoms with tolerable adverse effects (Biederman et al., Atomoxetine ADHD Study Group, 2002; Buitelaar et al., 2004; Cheng, Chen, Ko, & Ng, 2007; Escobar et al., 2005; Kelsey et al., 2004; Michelson et al., 2002).”
BackgroundLecavalier, L. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0147-5 · Cited by 569 · cited 1×
“Lecavalier (2006) found that children with PPD displayed behavior and emotional problems including symptoms associated with attention deficit and hyperactivity.”
Background(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 2×
“…could be a potential alternative treatment for attention deficit and hyperactive symptoms with tolerable adverse effects (Biederman et al., Atomoxetine ADHD Study Group, 2002; Buitelaar et al., 2004; Cheng, Chen, Ko, & Ng, 2007; Escobar et al., 2005; Kelsey et al., 2004; Michelson et al., 2002).”
BackgroundGoldstein, S., & Schwebach, A. J. (2004) · Journal of Autism and Developmental Disorders · doi:10.1023/b:jadd.0000029554.46570.68 · Cited by 412 · cited 1×
“Children with PDD who exhibited attention deficit and hyperactive symptoms were found to have greater difficulty in daily activities than children with PDD without attention deficit and hyperactive symptoms (Goldstein & Schwebach, 2004).”
BackgroundHanden, B. L., Johnson, C. R., & Lubetsky, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005548619694 · Cited by 326
Research works printed but not linked: 3
- Aman M. G., 1985, American Journal of Mental Deficiency, 89, 485
- Arnold L. E., 2006, Journal of the American Academy of Child and Adolescent Psychiatry, 45, 10
- Escobar R., 2005, Actas Españolas de Psiquiatría, 33, 26
Cited by
Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Davis, N. O., & Kollins, S. H. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0126-9 · Cited by 156
Psychopharmacological interventions in autism spectrum disorder
Accordino, R. E., Kidd, C., Politte, L. C., Henry, C. A., & McDougle, C. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1154536 · Cited by 126
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“At least six studies indicate that atomoxetine may be an effective treatment for ADHD symptoms in patients with co-morbid pervasive developmental disorders [138, 155– 160], although five of these studies are small (B16 patients), with treatment durations up to 10 weeks [138, 157–160].”
BackgroundBushe, C. J., & Savill, N. C. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113478475 · Cited by 72
Vahabzadeh, A. B. N., Keshav, N. U., Salisbury, J. P., & Sahin, N. T. (2018) · JMIR Mental Health · doi:10.2196/mental.9631 · Cited by 80
Metadata
- Authors
- Charnsil, C.
- Affiliations
- Chiang Mai University (TH)
- Corresponding author
- Charnsil, Chawanun
- Venue
- Journal of Attention Disorders
- Publisher
- SAGE Publications
- Published
- 2010-08-04
- Volume
- 15
- Issue
- 8
- Pages
- 684-689
- ISSN
- 1087-0547 (ISSN-L)
- 1557-1246
- OpenAlex
- W2051954276
- Cited by
- 36
- References
- 25
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 2 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 5 · 2014: 4 · 2013: 5 · 2012: 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Attention Disorders (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, autism spectrum disorder, severe autism, children, ADHD symptoms, hyperactivity, Aberrant Behavior Checklist, CGI-I
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Autistic Disorder, Child, Female, Humans, Male, Pilot Projects, Propylamines, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD: An Open-Label Study. https://app.cochat.ai/papers/10.1177/1087054710376907
- The paper
- Charnsil, C. (2011). Efficacy of Atomoxetine in Children With Severe Autistic Disorders and Symptoms of ADHD: An Open-Label Study. Journal of Attention Disorders. https://doi.org/10.1177/1087054710376907
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.